Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neuroscience Bulletin
Published in: Neuroscience Bulletin 8/2021

01-08-2021 | Alzheimer's Disease | Review

Emerging Role of PD-1 in the Central Nervous System and Brain Diseases

Authors: Junli Zhao, Alexus Roberts, Zilong Wang, Justin Savage, Ru-Rong Ji

Published in: Neuroscience Bulletin | Issue 8/2021

Login to get access

Abstract

Programmed cell death protein 1 (PD-1) is an immune checkpoint modulator and a major target of immunotherapy as anti-PD-1 monoclonal antibodies have demonstrated remarkable efficacy in cancer treatment. Accumulating evidence suggests an important role of PD-1 in the central nervous system (CNS). PD-1 has been implicated in CNS disorders such as brain tumors, Alzheimer’s disease, ischemic stroke, spinal cord injury, multiple sclerosis, cognitive function, and pain. PD-1 signaling suppresses the CNS immune response via resident microglia and infiltrating peripheral immune cells. Notably, PD-1 is also widely expressed in neurons and suppresses neuronal activity via downstream Src homology 2 domain-containing protein tyrosine phosphatase 1 and modulation of ion channel function. An improved understanding of PD-1 signaling in the cross-talk between glial cells, neurons, and peripheral immune cells in the CNS will shed light on immunomodulation, neuromodulation, and novel strategies for treating brain diseases.
Literature
1.
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992, 11: 3887–3895.PubMedPubMedCentralCrossRef
2.
Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996, 8: 765–772.PubMedCrossRef
3.
4.
Dong HD, Zhu GF, Tamada K, Chen LP. B7–H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999, 5: 1365–1369.PubMedCrossRef
5.
Freeman GJ, Long AJ, Iwai Y, Latchman Y, Bourque K, Brown JA, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7-family member leads to negative regulation of lymphocyte activation. Blood 2000, 96: 810a–811a.
6.
Latchman Y, Wood C, Chemova T, Iwai Y, Malenkovich N, Long A, et al. PD-L2, a novel B7 homologue, is a second ligand for PD-1 and inhibits T cell activation. FASEB J 2001, 15: A345–A345.
7.
Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001, 193: 839–845.PubMedPubMedCentralCrossRef
8.
Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002, 169: 5538–5545.PubMedCrossRef
9.
Sugita S, Usui Y, Horie S, Futagami Y, Aburatani H, Okazaki T, et al. T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions. Invest Ophthalmol Vis Sci 2009, 50: 2862–2870.PubMedCrossRef
10.
Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 2003, 33: 2706–2716.PubMedCrossRef
11.
Hu J, He H, Yang Z, Zhu G, Kang L, Jing X, et al. Programmed death ligand-1 on microglia regulates Th1 differentiation via nitric oxide in experimental autoimmune encephalomyelitis. Neurosci Bull 2016, 32: 70–82.PubMedPubMedCentralCrossRef
12.
13.
Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 2007, 19: 309–314.PubMedCrossRef
14.
Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11: 141–151.PubMedCrossRef
15.
Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001, 291: 319–322.PubMedCrossRef
16.
Dong HD, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7–H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002, 8: 793–800.PubMedCrossRef
17.
Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong HD, Webster WS, et al. Costimulatory B7–H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. J Urol 2005, 173: 169–169.CrossRef
18.
Zhao S, Li F, Leak RK, Chen J, Hu X. Regulation of neuroinflammation through programed death-1/programed death ligand signaling in neurological disorders. Front Cell Neurosci 2014, 8: 271.PubMedPubMedCentralCrossRef
19.
Chen G, Kim YH, Li H, Luo H, Liu DL, Zhang ZJ, et al. PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. Nat Neurosci 2017, 20: 917–926.PubMedPubMedCentralCrossRef
20.
Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015, 523: 337–341.PubMedPubMedCentralCrossRef
21.
Alves de Lima K, Rustenhoven J, Kipnis J. Meningeal immunity and its function in maintenance of the central nervous system in health and disease. Annu Rev Immunol 2020, 38: 597–620.PubMedCrossRef
22.
Ren X, Akiyoshi K, Vandenbark AA, Hurn PD, Offner H. Programmed death-1 pathway limits central nervous system inflammation and neurologic deficits in murine experimental stroke. Stroke 2011, 42: 2578–2583.PubMedPubMedCentralCrossRef
23.
Yao A, Liu F, Chen K, Tang L, Liu L, Zhang K, et al. Programmed death 1 deficiency induces the polarization of macrophages/microglia to the M1 phenotype after spinal cord injury in mice. Neurotherapeutics 2014, 11: 636–650.PubMedPubMedCentralCrossRef
24.
Jiang C, Wang Z, Donnelly CR, Wang K, Andriessen AS, Tao X, et al. PD-1 regulates GABAergic neurotransmission and GABA-mediated analgesia and anesthesia. iScience 2020, 23: 101570.PubMedPubMedCentralCrossRef
25.
26.
27.
28.
Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004, 173: 945–954.PubMedCrossRef
29.
Quigley M, Pereyra F, Nilsson B, Porichis F, Fonseca C, Eichbaum Q, et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med 2010, 16: 1147–1151.PubMedPubMedCentralCrossRef
30.
Lu D, Ni Z, Liu X, Feng S, Dong X, Shi X, et al. Beyond T Cells: understanding the role of PD-1/PD-L1 in tumor-associated macrophages. J Immunol Res 2019, 2019: 1919082.PubMedPubMedCentralCrossRef
31.
Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 2017, 545: 495–499.PubMedPubMedCentralCrossRef
32.
Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 2009, 29: 13435–13444.PubMedPubMedCentralCrossRef
33.
Ransohoff RM. A polarizing question: do M1 and M2 microglia exist?. Nat Neurosci 2016, 19: 987–991.PubMedCrossRef
34.
Chen G, Zhang YQ, Qadri YJ, Serhan CN, Ji RR. Microglia in pain: detrimental and protective roles in pathogenesis and resolution of pain. Neuron 2018, 100: 1292–1311.PubMedPubMedCentralCrossRef
35.
36.
Ohmori Y, Hamilton TA. IL-4-induced STAT6 suppresses IFN-gamma-stimulated STAT1-dependent transcription in mouse macrophages. J Immunol 1997, 159: 5474–5482.PubMedCrossRef
37.
Zhang Y, Ma CJ, Ni L, Zhang CL, Wu XY, Kumaraguru U, et al. Cross-talk between programmed death-1 and suppressor of cytokine signaling-1 in inhibition of IL-12 production by monocytes/macrophages in hepatitis C virus infection. J Immunol 2011, 186: 3093–3103.PubMedCrossRef
38.
Zhuang ZY, Gerner P, Woolf CJ, Ji RR. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005, 114: 149–159.PubMedCrossRef
39.
Katsura H, Obata K, Mizushima T, Sakurai J, Kobayashi K, Yamanaka H, et al. Activation of Src-family kinases in spinal microglia contributes to mechanical hypersensitivity after nerve injury. J Neurosci 2006, 26: 8680–8690.PubMedPubMedCentralCrossRef
40.
Chen G, Luo X, Qadri MY, Berta T, Ji RR. Sex-dependent glial signaling in pathological pain: distinct roles of spinal microglia and astrocytes. Neurosci Bull 2018, 34: 98–108.PubMedCrossRef
41.
Chen Q, Xu LX, Du TJ, Hou YX, Fan WJ, Wu QL, et al. Enhanced expression of PD-L1 on microglia after surgical brain injury exerts self-protection from inflammation and promotes neurological repair. Neurochem Res 2019, 44: 2470–2481.PubMedCrossRef
42.
Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer Res 2019, 38: 87.PubMedPubMedCentralCrossRef
43.
44.
45.
46.
Cavaco M, Gaspar D, Arb Castanho M, Neves V. Antibodies for the treatment of brain metastases, a dream or a reality? Pharmaceutics 2020, 12.
47.
Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer 2020, 20: 12–25.PubMedCrossRef
48.
Guldner IH, Wang Q, Yang L, Golomb SM, Zhao Z, Lopez JA, et al. CNS-native myeloid cells drive immune suppression in the brain metastatic niche through Cxcl10. Cell 2020, 183: 1234–1248. e25.PubMedCrossRefPubMedCentral
49.
Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell 2020, 182: 886–900. e17.PubMedCrossRefPubMedCentral
50.
Katzenelenbogen Y, Sheban F, Yalin A, Yofe I, Svetlichnyy D, Jaitin DA, et al. Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. Cell 2020, 182: 872–885. e19.PubMedCrossRef
51.
Zhao, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med 2019, 25: 462–469.PubMedPubMedCentralCrossRef
52.
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 2016, 17: 976–983.PubMedPubMedCentralCrossRef
53.
Feng S, Coward J, McCaffrey E, Coucher J, Kalokerinos P, O’Byrne K. Pembrolizumab-Induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors. J Thorac Oncol 2017, 12: 1626–1635.PubMedCrossRef
54.
Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 2017, 74: 1216–1222.PubMedPubMedCentralCrossRef
55.
McGinnis GJ, Raber J. CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy. Immunotherapy 2017, 9: 929–941.PubMedPubMedCentralCrossRef
56.
Mirabile A, Brioschi E, Ducceschi M, Piva S, Lazzari C, Bulotta A, et al. PD-1 inhibitors-related neurological toxicities in patients with non-small-cell lung cancer: a literature review. Cancers (Basel) 2019, 11.
57.
Fan DY, Wang YJ. Early intervention in Alzheimer’s disease: how early is early enough? Neurosci Bull 2020, 36: 195–197.PubMedCrossRef
58.
Bharadwaj PR, Dubey AK, Masters CL, Martins RN, Macreadie IG. Abeta aggregation and possible implications in Alzheimer’s disease pathogenesis. J Cell Mol Med 2009, 13: 412–421.PubMedPubMedCentralCrossRef
59.
Saresella M, Calabrese E, Marventano I, Piancone F, Gatti A, Farina E, et al. A potential role for the PD1/PD-L1 pathway in the neuroinflammation of Alzheimer’s disease. Neurobiol Aging 2012, 33: e611-622.CrossRef
60.
Torres KC, Araujo Pereira P, Lima GS, Bozzi IC, Rezende VB, Bicalho MA, et al. Increased frequency of T cells expressing IL-10 in Alzheimer disease but not in late-onset depression patients. Prog Neuropsychopharmacol Biol Psychiatry 2013, 47: 40–45.PubMedCrossRef
61.
Guillot-Sestier MV, Doty KR, Gate D, Rodriguez J Jr, Leung BP, Rezai-Zadeh K, et al. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 2015, 85: 534–548.PubMedPubMedCentralCrossRef
62.
Koronyo-Hamaoui M, Ko MHK, Koronyo Y, Azoulay D, Seksenyan A, Kunis G, et al. Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J Neurochem 2009, 111: 1409–1424.PubMedCrossRef
63.
Kunis G, Baruch K, Rosenzweig N, Kertser A, Miller O, Berkutzki T, et al. IFN-gamma-dependent activation of the brain’s choroid plexus for CNS immune surveillance and repair. Brain 2013, 136: 3427–3440.PubMedCrossRef
64.
Rosenzweig N, Dvir-Szternfeld R, Tsitsou-Kampeli A, Keren-Shaul H, Ben-Yehuda H, Weill-Raynal P, et al. PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nat Commun 2019, 10: 465.PubMedPubMedCentralCrossRef
65.
Baruch K, Deczkowska A, Rosenzweig N, Tsitsou-Kampeli A, Sharif AM, Matcovitch-Natan O, et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease. Nat Med 2016, 22: 135–137.PubMedCrossRef
66.
Lin Y, Rajamohamedsait HB, Sandusky-Beltran LA, Gamallo-Lana B, Mar A, Sigurdsson EM. Chronic PD-1 checkpoint blockade does not affect cognition or promote tau clearance in a tauopathy mouse model. Front Aging Neurosci 2019, 11: 377.PubMedCrossRef
67.
Latta-Mahieu M, Elmer B, Bretteville A, Wang YM, Lopez-Grancha M, Goniot P, et al. Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-beta burden in several amyloid transgenic mouse models. Glia 2018, 66: 492–504.PubMedCrossRef
68.
Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999, 22: 391–397.PubMedCrossRef
69.
Bodhankar S, Chen YX, Vandenbark AA, Murphy SJ, Offner H. IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke. Metab Brain Dis 2013, 28: 375–386.PubMedPubMedCentralCrossRef
70.
Ren XF, Akiyoshi K, Dziennis S, Vandenbark AA, Herson PS, Hurn PD, et al. Regulatory B cells limit CNS inflammation and neurologic deficits in murine experimental stroke. J Neurosci 2011, 31: 8556–8563.PubMedPubMedCentralCrossRef
71.
Li PY, Mao LL, Liu XR, Gan Y, Zheng J, Thomson AW, et al. Essential role of program death 1-ligand 1 in regulatory T-cell-afforded protection against blood-brain barrier damage after stroke. Stroke 2014, 45: 857–864.PubMedPubMedCentralCrossRef
72.
Bodhankar S, Chen YX, Lapato A, Dotson AL, Wang JM, Vandenbark AA, et al. PD-L1 monoclonal antibody treats ischemic stroke by controlling central nervous system inflammation. Stroke 2015, 46: 2926–2934.PubMedPubMedCentralCrossRef
73.
Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1. J Neuroinflammation 2013, 10: 111.PubMedPubMedCentralCrossRef
74.
Han R, Luo J, Shi Y, Yao Y, Hao J. PD-L1 (programmed death ligand 1) protects against experimental intracerebral hemorrhage-induced brain injury. Stroke 2017, 48: 2255–2262.PubMedCrossRef
75.
Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006, 12: 441–445.PubMedCrossRef
76.
Kawasaki Y, Xu ZZ, Wang X, Park JY, Zhuang ZY, Tan PH, et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008, 14: 331–336.PubMedPubMedCentralCrossRef
77.
Li G, Fan ZK, Gu GF, Jia ZQ, Zhang QQ, Dai JY, et al. Epidural spinal cord stimulation promotes motor functional recovery by enhancing oligodendrocyte survival and differentiation and by protecting myelin after spinal cord injury in rats. Neurosci Bull 2020, 36: 372–384.PubMedCrossRef
78.
Huang Q, Duan W, Sivanesan E, Liu S, Yang F, Chen Z, et al. Spinal cord stimulation for pain treatment after spinal cord injury. Neurosci Bull 2019, 35: 527–539.PubMedCrossRef
79.
Hulsebosch CE, Hains BC, Crown ED, Carlton SM. Mechanisms of chronic central neuropathic pain after spinal cord injury. Brain Res Rev 2009, 60: 202–213.PubMedCrossRef
80.
Donnelly DJ, Popovich PG. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol 2008, 209: 378–388.PubMedCrossRef
81.
Zha J, Smith A, Andreansky S, Bracchi-Ricard V, Bethea JR. Chronic thoracic spinal cord injury impairs CD8+ T-cell function by up-regulating programmed cell death-1 expression. J Neuroinflammation 2014, 11: 65.PubMedPubMedCentralCrossRef
82.
He HF, Zhou YY, Zhou YL, Zhuang JY, He X, Wang SY, et al. Dexmedetomidine mitigates microglia-mediated neuroinflammation through upregulation of programmed cell death protein 1 in a rat spinal cord injury model. J Neurotrauma 2018, 35: 2591–2603.PubMedCrossRef
83.
84.
Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M, et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol 2009, 183: 4984–4993.PubMedCrossRef
85.
Kroner A, Mehling M, Hemmer B, Rieckmann P, Toyka KV, Maurer M, et al. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 2005, 58: 50–57.PubMedCrossRef
86.
Ortler S, Leder C, Mittelbronn M, Zozulya AL, Knolle PA, Chen L, et al. B7–H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis. Eur J Immunol 2008, 38: 1734–1744.PubMedCrossRef
87.
Salama AD, Chitnis T, Imitola J, Ansari MJ, Akiba H, Tushima F, et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 2003, 198: 71–78.PubMedPubMedCentralCrossRef
88.
Harari D, Kuhn N, Abramovich R, Sasson K, Zozulya AL, Smith P, et al. Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis. J Biol Chem 2014, 289: 29014–29029.PubMedPubMedCentralCrossRef
89.
Carter LL, Leach MW, Azoitei ML, Cui J, Pelker JW, Jussif J, et al. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 2007, 182: 124–134.PubMedCrossRef
90.
Bodhankar S, Wang C, Vandenbark AA, Offner H. Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells. Eur J Immunol 2011, 41: 1165–1175.PubMedPubMedCentralCrossRef
91.
Cheng X, Zhao Z, Ventura E, Gran B, Shindler KS, Rostami A. The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma. J Neuroimmunol 2007, 185: 75–86.PubMedPubMedCentralCrossRef
92.
93.
Xiao X, Zhao XT, Xu LC, Yue LP, Liu FY, Cai J, et al. Shp-1 dephosphorylates TRPV1 in dorsal root ganglion neurons and alleviates CFA-induced inflammatory pain in rats. Pain 2015, 156: 597–608.PubMedCrossRef
94.
Liu BL, Cao QL, Zhao X, Liu HZ, Zhang YQ. Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia. JCI Insight 2020, 5.
95.
Wang Z, Jiang C, He Q, Matsuda M, Han Q, Wang K, et al. Anti-PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates. Sci Transl Med 2020, 12.
96.
97.
Acosta C, Djouhri L, Watkins R, Berry C, Bromage K, Lawson SN. TREK2 expressed selectively in IB4-binding C-fiber nociceptors hyperpolarizes their membrane potentials and limits spontaneous pain. J Neurosci 2014, 34: 1494–1509.PubMedPubMedCentralCrossRef
98.
Wang K, Gu Y, Liao Y, Bang S, Donnelly CR, Chen O, et al. PD-1 blockade inhibits osteoclast formation and murine bone cancer pain. J Clin Invest 2020, 130: 3603–3620.PubMedPubMedCentralCrossRef
99.
Yuan LL, Adams JP, Swank M, Sweatt JD, Johnston D. Protein kinase modulation of dendritic K+ channels in hippocampus involves a mitogen-activated protein kinase pathway. J Neurosci 2002, 22: 4860–4868.PubMedPubMedCentralCrossRef
100.
Thibult ML, Mamessier E, Gertner-Dardenne J, Pastor S, Just-Landi S, Xerri L, et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol 2013, 25: 129–137.PubMedCrossRef
101.
Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol 2017, 14: 203–220.PubMedCrossRef
102.
Wang X, Wang G, Wang Z, Liu B, Han N, Li J, et al. PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1/PD-L1-dependent pathway. Mol Immunol 2019, 109: 20–26.PubMedCrossRef
103.
Lim TS, Chew V, Sieow JL, Goh S, Yeong JP, Soon AL, et al. PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity. Oncoimmunology 2016, 5: e1085146.PubMedCrossRef
104.
Yao S, Wang S, Zhu Y, Luo L, Zhu G, Flies S, et al. PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood 2009, 113: 5811–5818.PubMedPubMedCentralCrossRef
105.
106.
Bally AP, Lu P, Tang Y, Austin JW, Scharer CD, Ahmed R, et al. NF-κB regulates PD-1 expression in macrophages. J Immunol 2015, 194: 4545–4554.PubMedCrossRef
107.
Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A 2009, 106: 6303–6308.PubMedPubMedCentralCrossRef
108.
Norris S, Coleman A, Kuri-Cervantes L, Bower M, Nelson M, Goodier MR. PD-1 expression on natural killer cells and CD8+ T cells during chronic HIV-1 infection. Viral Immunol 2012, 25: 329–332.PubMedCrossRef
109.
Concha-Benavente F, Kansy B, Moskovitz J, Moy J, Chandran U, Ferris RL. PD-L1 mediates dysfunction in activated PD-1+ NK cells in head and neck cancer patients. Cancer Immunol Res 2018, 6: 1548–1560.PubMedPubMedCentralCrossRef
110.
Chen L, Sham CW, Chan AM, Francisco LM, Wu Y, Mareninov S, et al. Role of the immune modulator programmed cell death-1 during development and apoptosis of mouse retinal ganglion cells. Invest Ophthalmol Vis Sci 2009, 50: 4941–4948.PubMedCrossRef
111.
Wang W, Chan A, Qin Y, Kwong JMK, Caprioli J, Levinson R, et al. Programmed cell death-1 is expressed in large retinal ganglion cells and is upregulated after optic nerve crush. Exp Eye Res 2015, 140: 1–9.PubMedPubMedCentralCrossRef
112.
Fourcade J, Sun ZJ, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010, 207: 2175–2186.PubMedPubMedCentralCrossRef
113.
Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013, 73: 128–138.PubMedCrossRef
114.
Mizuno R, Sugiura D, Shimizu K, Maruhashi T, Watada M, Okazaki IM, et al. PD-1 primarily targets TCR signal in the inhibition of functional T cell activation. Front Immunol 2019, 10: 630.PubMedPubMedCentralCrossRef
115.
116.
Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 2019, 25: 477–486.PubMedPubMedCentralCrossRef
117.
Caccese M, Indraccolo S, Zagonel V, Lombardi G. PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review. Crit Rev Oncol Hematol 2019, 135: 128–134.PubMedCrossRef
118.
Litak J, Mazurek M, Grochowski C, Kamieniak P, Rolinski J. PD-L1/PD-1 axis in glioblastoma multiforme. Int J Mol Sci 2019, 20.
119.
Hardcastle J, Mills L, Malo CS, Jin F, Kurokawa C, Geekiyanage H, et al. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro-Oncol 2017, 19: 493–502.PubMed
120.
Hugo W, Zaretsky JM, Sun L, Song CY, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2016, 165: 35–44.PubMedPubMedCentralCrossRef
121.
Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 2015, 162: 1242–1256.PubMedPubMedCentralCrossRef
122.
Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018, 359: 97–103.PubMedCrossRef
123.
Matson V, Fessler J, Bao R, Chongsuwat T, Zha YY, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 2018, 359: 104–108.PubMedPubMedCentralCrossRef
124.
Pittet CL, Newcombe J, Prat A, Arbour N. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. J Neuroinflammation 2011, 8: 155.PubMedPubMedCentralCrossRef
125.
Javan MR, Aslani S, Zamani MR, Rostamnejad J, Asadi M, Farhoodi M, et al. Downregulation of immunosuppressive molecules, PD-1 and PD-L1 but not PD-L2, in the patients with multiple sclerosis. Iran J Allergy Asthma Immunol 2016, 15: 296–302.PubMed
126.
Shi S, Han Y, Wang D, Guo P, Wang J, Ren T, et al. PD-L1 and PD-1 expressed in trigeminal ganglia may inhibit pain in an acute migraine model. Cephalalgia 2020, 40: 288–298.PubMedCrossRef
127.
128.
Zhang J, Zhang H, Luo Y. Association between activation of the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway and pain in patients with cancer. Med Sci Monit 2019, 25: 1275–1282.PubMedPubMedCentralCrossRef
Metadata
Title
Emerging Role of PD-1 in the Central Nervous System and Brain Diseases
Authors
Junli Zhao
Alexus Roberts
Zilong Wang
Justin Savage
Ru-Rong Ji
Publication date
01-08-2021
Publisher
Springer Singapore
Published in
Neuroscience Bulletin / Issue 8/2021
Print ISSN: 1673-7067
Electronic ISSN: 1995-8218
DOI
https://doi.org/10.1007/s12264-021-00683-y

Other articles of this Issue 8/2021

Neuroscience Bulletin 8/2021 Go to the issue

Review

Evolving Models and Tools for Microglial Studies in the Central Nervous System

Letter to the Editor

GABA Signaling Pathway-associated Gene PLCL1 Rare Variants May be Associated with Autism Spectrum Disorders

RESEARCH HIGHLIGHT

Heteromolecular Plasticity in Striatal Astrocytes

Original Article

An Intronic Variant of CHD7 Identified in Autism Patients Interferes with Neuronal Differentiation and Development

Letter to the Editor

Functional Near-Infrared Spectroscopy Neurofeedback of Cortical Target Enhances Hippocampal Activation and Memory Performance

Original Article

Dicer Deletion in Astrocytes Inhibits Oligodendroglial Differentiation and Myelination